Generic Venclexta Availability

Last updated on Apr 10, 2025.

Venclexta is a brand name of venetoclax, approved by the FDA in the following formulation(s):

VENCLEXTA (venetoclax - tablet;oral)

• Manufacturer: ABBVIE
  Approval date: April 11, 2016
  Strength(s): 10MG ^[RLD], 50MG ^[RLD], 100MG ^[RLD]

Is there a generic version of Venclexta available?

No. There is currently no therapeutically equivalent version of Venclexta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Venclexta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Salts and crystalline forms of an apoptosis-inducing agent
  Patent 10,730,873
  Issued: August 4, 2020
  Inventor(s): Catron Nathaniel & Chen Shuang & Gong Yuchuan & Zhang Geoff G.
  Assignee(s): AbbVie Inc.
  

  Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  Patent expiration dates:

  • November 21, 2031
    
    ✓ 
    Drug substance
• Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
  Patent 10,993,942
  Issued: May 4, 2021
  Inventor(s): Sampath; Deepak et al.
  Assignee(s): GENENTECH, INC. (South San Francisco, CA); HOFFMANN-LA ROCHE INC. (Little Falls, NJ); ABBVIE INC. (North Chicago, IL)
  

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

  Patent expiration dates:

  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
• Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
  Patent 11,110,087
  Issued: September 7, 2021
  Inventor(s): Sampath; Deepak et al.
  Assignee(s): GENENTECH, INC. (South San Francisco, CA); HOFFMANN-LA ROCHE INC. (Little Falls, NJ); ABBVIE INC. (North Chicago, IL)
  

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

  Patent expiration dates:

  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
• Melt-extruded solid dispersions containing an apoptosis-inducing agent
  Patent 11,369,599
  Issued: June 28, 2022
  Inventor(s): Birtalan; Esther et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL); AbbVie Deutschland GMBH & Co KG (Wiesbaden, DE)
  

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

  Patent expiration dates:

  • May 23, 2032
    
    ✓ 
    Drug product
• Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
  Patent 11,413,282
  Issued: August 16, 2022
  Inventor(s): Sampath; Deepak et al.
  Assignee(s): GENENTECH, INC. (South San Francisco, CA); HOFFMANN-LA ROCHE INC. (Little Falls, NJ); ABBVIE INC. (North Chicago, IL)
  

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

  Patent expiration dates:

  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB
• Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
  Patent 11,590,128
  Issued: February 28, 2023
  Inventor(s): Sampath; Deepak et al.
  Assignee(s): GENENTECH, INC. (South San Francisco, CA); HOFFMANN-LA ROCHE INC. (Little Falls, NJ); ABBVIE INC. (North Chicago, IL)
  

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

  Patent expiration dates:

  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF AML BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE TO ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES PER A DOSE RAMP-UP INCLUDING AN INITIAL 100 MG OR A FINAL 400 MG PER DAY DOSE
• Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
  Patent 8,546,399
  Issued: October 1, 2013
  Inventor(s): Bruncko Milan & Ding Hong & Doherty George A. & Elmore Steven W. & Hasvold Lisa A. & Hexamer Laura & Kunzer Aaron R. & Song Xiaohong & Souers Andrew J. & Sullivan Gerard M. & Tao Zhi-Fu & Wang Gary T. & Wang Le & Wang Xilu & Wendt Michael D. & Mantei Robert & Hansen Todd M.
  Assignee(s): Abbvie Inc.
  

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  Patent expiration dates:

  • June 27, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Salts and crystalline forms of an apoptosis-inducing agent
  Patent 8,722,657
  Issued: May 13, 2014
  Inventor(s): Catron Nathaniel & Chen Shuang & Gong Yuchuan & Zhang Geoff G.
  Assignee(s): Abbvie Inc.
  

  Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  Patent expiration dates:

  • January 29, 2032
    
    ✓ 
    Drug substance
• Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
  Patent 9,174,982
  Issued: November 3, 2015
  Inventor(s): Bruncko; Milan et al.
  Assignee(s): ABBVIE INC. (North Chicago, IL); GENENTECH, INC. (South San Francisco, CA); THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Parkville, AU)
  

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  Patent expiration dates:

  • May 26, 2030
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
  • May 26, 2030
    
    ✓ 
    Patent use: TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
  • May 26, 2030
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
  • May 26, 2030
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
• Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
  Patent 9,539,251
  Issued: January 10, 2017
  Inventor(s): Sampath; Deepak et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA); F. Hoffmann-La Roche AG (Basel, CH)
  

  The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

  Patent expiration dates:

  • September 6, 2033
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • June 8, 2025 - INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
  • November 21, 2025 - INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
  • May 15, 2026 - TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer